An antithrombin-targeting RNAi therapy for hemophilia, fitusiran, developed by Alnylam Pharmaceuticals Inc. with Sanofi Genzyme, is entering phase III territory. The three-part Atlas trial program, in hemophilia A and B, is expected to yield top-line data in mid to late 2019. Its start, just days before results of an ongoing phase II study are scheduled to be detailed at a Berlin medical meeting, triggers a $25 million milestone payment for Alnylam and marks the kick-off of the last leg in a race to approval with Roche Holding AG's bispecific monoclonal antibody emicizumab.